During the corresponding time, Arcellx Inc saw a revenue deteriorated by -89.17 % year on year, sequentially revenue fell by -66.58 %. While revenue at the Arcellx Inc 's corporate clients
Arcellx Inc's Comment on Sales, Marketing and Customers
The company operates in the oncology, CAR-T therapies, and rare diseases markets, focusing on the development of immunotherapies, including autologous CAR-T solutions. Its pipeline includes expansion into solid tumor indications and non-oncology indications. The company maintains strategic collaborations with firms such as Kite to utilize their platform technologies. The leadership team has experience across oncology, biotechnology, and commercial sectors, with previous roles at Nevro, Johnson & Johnson Development Corporation, Precision Biosciences, Bavarian Nordic, and Canaccord Genuity. The company prioritizes diversity and inclusion within its workforce and leadership to build high-performance teams with diverse representation.
Arcellx Inc. (NASDAQ: ACLX), based in Redwood City, California, and Kite, a Gilead Company (NASDAQ: GILD), based in Santa Monica, California, have announced their operational updates today on their jointly developed anitocabtagene autoleucel (anito-cel) multiple myeloma program. Despite facing a substantial decline in sequential revenue, Arcellx has continued to prioritize advancements within its specialized line of therapeutics under the banner of its multiple myeloma program an effort that underlines the company s focus on developing novel and transformational treatments for cancer patients. Anito-cel is recognized as the first BCMA CAR T to be investigated in multiple myeloma using Arcellx s unique and co...
Arcellx Inc’s Comment on Sales, Marketing and Customers
The company operates in the oncology, CAR-T therapies, and rare diseases markets, focusing on the development of immunotherapies, including autologous CAR-T solutions. Its pipeline includes expansion into solid tumor indications and non-oncology indications. The company maintains strategic collaborations with firms such as Kite to utilize their platform technologies. The leadership team has experience across oncology, biotechnology, and commercial sectors, with previous roles at Nevro, Johnson & Johnson Development Corporation, Precision Biosciences, Bavarian Nordic, and Canaccord Genuity. The company prioritizes diversity and inclusion within its workforce and leadership to build high-performance teams with diverse representation.
Sources:
Arcellx Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Arcellx Inc’s corporate clients.
For your research, we’ve provided 9 tables on Arcellx Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
